AIM ImmunoTech (AIM) News Today → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free AIM Stock Alerts $0.43 +0.02 (+4.90%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAIM ImmunoTech Announces Release of the Next CEO Corner Segmentglobenewswire.com - April 25 at 8:45 AMCritical Survey: AIM ImmunoTech (NYSE:AIM) versus Invivyd (NASDAQ:IVVD)americanbankingnews.com - April 21 at 1:26 AMAIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programsfinanznachrichten.de - April 15 at 9:00 PMAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programsglobenewswire.com - April 15 at 8:55 AMAIM ImmunoTech Announces Release of the Next CEO Corner Segmentglobenewswire.com - April 11 at 11:00 AMAim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumabmarkets.businessinsider.com - April 10 at 10:49 AMAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancerglobenewswire.com - April 10 at 8:21 AMNearly 600 cars recovered in sweeping auto theft crackdown in Ontario, Quebec: policeca.news.yahoo.com - April 5 at 1:45 AMEarnings call: AIM ImmunoTech optimistic on Ampligen's future in oncologyinvesting.com - April 4 at 3:44 PMAIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcriptinsidermonkey.com - April 3 at 9:23 AMQ4 2023 AIM ImmunoTech Inc Earnings Callfinance.yahoo.com - April 2 at 11:20 PMAIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023markets.businessinsider.com - April 2 at 12:49 PMAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 2 at 7:30 AMAIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conferenceglobenewswire.com - March 28 at 8:05 AMAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcastglobenewswire.com - March 26 at 9:05 AMAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Researchglobenewswire.com - March 25 at 9:05 AMAIM ImmunoTech Inc. (NYSE:AIM) Director Purchases $15,000.18 in Stockinsidertrades.com - March 23 at 9:28 AMAIM ImmunoTech Announces Release of the Next CEO Corner Segmentglobenewswire.com - March 22 at 8:55 AMAIM ImmunoTech Announces Release of the Next CEO Corner Segmentglobenewswire.com - March 20 at 9:25 AMAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 37,879 Sharesinsidertrades.com - March 19 at 5:55 AMAIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunityglobenewswire.com - March 15 at 8:45 AMAIM ImmunoTech launches CEO Corner for direct stakeholder engagementinvesting.com - March 9 at 3:55 PMAIM ImmunoTech Announces Launch of CEO Corner Platformglobenewswire.com - March 7 at 8:45 AMAIM ImmunoTech Inc.: AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Updatefinanznachrichten.de - February 29 at 9:30 AMAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Updateglobenewswire.com - February 29 at 8:45 AMBuy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline Developmentsmarkets.businessinsider.com - February 15 at 10:40 PMAIM ImmunoTech commences dosing in pancreatic cancer therapy trialmsn.com - February 15 at 12:39 PMAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancerfinance.yahoo.com - February 14 at 9:32 AMAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancerglobenewswire.com - February 14 at 8:55 AMAIM ImmunoTech Touts Ampligen’s Post-COVID Study Successmsn.com - February 10 at 8:44 AMAIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditionsfinanznachrichten.de - February 9 at 12:23 AMAIM stock dips amid mixed results for post-COVID fatigue therapymsn.com - February 8 at 2:17 PMAIM ImmunoTech Stock (AMEX:AIM) Dividends: History, Yield and Datesbenzinga.com - February 5 at 7:53 AMPRISM MarketView Marks World Cancer Dayfinance.yahoo.com - February 2 at 12:25 PMAIM ImmunoTech Discloses Q1 Pancreatic Cancer Program Updatemsn.com - January 26 at 9:10 PMAIM ImmunoTech Gets Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligenmarkets.businessinsider.com - January 24 at 2:17 PMAIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancerfinance.yahoo.com - January 22 at 9:14 AMAIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meetingfinance.yahoo.com - January 5 at 5:36 PMDelaware Court Rules In Favor Of AIM ImmunoTech, Upholds Activist Group's Board Nominations Invalidmarkets.businessinsider.com - December 29 at 9:49 AMAIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buyingmsn.com - November 28 at 10:38 AMAIM ImmunoTech Inc.: AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patentsfinanznachrichten.de - November 27 at 6:08 PMAIM ImmunoTech concludes dosing in Phase II post-Covid drug trialmsn.com - November 22 at 5:54 PMAIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditionsfinance.yahoo.com - November 21 at 3:28 PMStrong Financial Position and Promising Clinical Trials Bolster Buy Rating for AIM ImmunoTech: An Analysis by Jason McCarthymarkets.businessinsider.com - November 18 at 12:54 AMKellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Changefinance.yahoo.com - November 16 at 10:47 AMAIM ImmunoTech Inc. (AMEX:AIM) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 16 at 10:47 AMAIM ImmunoTech Inc.: AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Updatefinanznachrichten.de - November 15 at 11:33 AMAIM ImmunoTech GAAP EPS of -$0.16 misses by $0.04msn.com - November 15 at 11:33 AMPreview: AIM ImmunoTech's Earningsbenzinga.com - November 14 at 12:41 PMAIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancerfinance.yahoo.com - November 14 at 12:41 PM Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address They say it’s ‘unstoppable’ – How I made 43,509% (Ad)Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss. Click here now for the full story. AIM Media Mentions By Week AIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.000.32▲Average Medical News Sentiment AIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼21▲AIM Articles Average Week Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EVAX News APTO News ZIVO News PLUR News SNTI News WINT News SRZN News COEP News INKT News IKT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
